113 related articles for article (PubMed ID: 26179339)
1. Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study.
White N; Flaherty I; Higgs P; Larance B; Nielsen S; Degenhardt L; Ali R; Lintzeris N
Drug Alcohol Rev; 2015 Nov; 34(6):623-9. PubMed ID: 26179339
[TBL] [Abstract][Full Text] [Related]
2. The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.
Larance B; Dietze P; Ali R; Lintzeris N; White N; Jenkinson R; Degenhardt L
Drug Alcohol Rev; 2015 Nov; 34(6):603-10. PubMed ID: 25950232
[TBL] [Abstract][Full Text] [Related]
3. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
[TBL] [Abstract][Full Text] [Related]
4. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
Gunderson EW; Hjelmström P; Sumner M;
Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
[TBL] [Abstract][Full Text] [Related]
5. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
Butler SF; Black RA; Severtson SG; Dart RC; Green JL
J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
[TBL] [Abstract][Full Text] [Related]
6. Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning.
Häkkinen M; Heikman P; Ojanperä I
Forensic Sci Int; 2013 Oct; 232(1-3):11-5. PubMed ID: 24053859
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film.
Gunderson EW; Sumner M
J Addict Med; 2016; 10(2):124-30. PubMed ID: 26918662
[TBL] [Abstract][Full Text] [Related]
8. Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia.
Larance B; Mattick R; Ali R; Lintzeris N; Jenkinson R; White N; Kihas I; Cassidy R; Degenhardt L
Drug Alcohol Rev; 2016 Jan; 35(1):83-91. PubMed ID: 26450513
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
Jönsson M; Mundin G; Sumner M
Eur J Pharm Sci; 2018 Sep; 122():125-133. PubMed ID: 29940217
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
[TBL] [Abstract][Full Text] [Related]
11. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.
Degenhardt L; Larance BK; Bell JR; Winstock AR; Lintzeris N; Ali RL; Scheuer N; Mattick RP
Med J Aust; 2009 Aug; 191(3):161-5. PubMed ID: 19645647
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
Larance B; Degenhardt L; Lintzeris N; Bell J; Winstock A; Dietze P; Mattick R; Ali R; Horyniak D
Drug Alcohol Depend; 2011 Nov; 118(2-3):265-73. PubMed ID: 21565452
[TBL] [Abstract][Full Text] [Related]
13. Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double-blind, within-subject, crossover study among opioid-dependent subjects.
Dhagudu NK; Ambekar A; Agrawal A; Rao R; Mishra AK; Jain R; Singh S
Drug Alcohol Rev; 2020 Jul; 39(5):595-603. PubMed ID: 32162420
[TBL] [Abstract][Full Text] [Related]
14. Overdose Risk and Client Characteristics Associated With the Injection of Buprenorphine at a Medically Supervised Injecting Center in Sydney, Australia.
Power J; Salmon AM; Latimer J; Jauncey M; Day CA
Subst Use Misuse; 2019; 54(10):1646-1653. PubMed ID: 30973286
[No Abstract] [Full Text] [Related]
15. Impact of a Mandated Change in Buprenorphine Formulation.
Graddy R; Rastegar DA
J Addict Med; 2017; 11(6):435-439. PubMed ID: 28742624
[TBL] [Abstract][Full Text] [Related]
16. 'It's Fast, It's Quick, It Stops Me Being Sick': How to influence preparation of opioid tablets for injection.
Lafferty L; Treloar C; van Breda N; Steele M; Hiley S; Flaherty I; Salmon A
Drug Alcohol Rev; 2017 Sep; 36(5):651-657. PubMed ID: 28493466
[TBL] [Abstract][Full Text] [Related]
17. Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.
Hoffman K; Peyton ML; Sumner M
J Addict Med; 2017; 11(3):217-223. PubMed ID: 28353467
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients.
Launonen E; Wallace I; Kotovirta E; Alho H; Simojoki K
Drug Alcohol Depend; 2016 May; 162():227-35. PubMed ID: 27068849
[TBL] [Abstract][Full Text] [Related]
19. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.
Vicknasingam B; Mazlan M; Schottenfeld RS; Chawarski MC
Drug Alcohol Depend; 2010 Sep; 111(1-2):44-9. PubMed ID: 20478668
[TBL] [Abstract][Full Text] [Related]
20. The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film.
White N; Ali R; Larance B; Zador D; Mattick RP; Degenhardt L
Drug Alcohol Rev; 2016 Jan; 35(1):76-82. PubMed ID: 26331899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
